Compare DSP & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | ORGO |
|---|---|---|
| Founded | 1999 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.6M | 239.3M |
| IPO Year | 2021 | 2016 |
| Metric | DSP | ORGO |
|---|---|---|
| Price | $12.62 | $1.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $17.81 | $8.50 |
| AVG Volume (30 Days) | 174.3K | ★ 638.1K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 157.14 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $344,201,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | 17.04 |
| 52 Week Low | $8.11 | $1.47 |
| 52 Week High | $14.80 | $7.08 |
| Indicator | DSP | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 29.25 |
| Support Level | $9.72 | N/A |
| Resistance Level | $13.42 | $2.57 |
| Average True Range (ATR) | 0.61 | 0.08 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 27.15 | 3.23 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.